Section 2: AKI Definition  by unknown
Section 2: AKI Definition
Kidney International Supplements (2012) 2, 19–36; doi:10.1038/kisup.2011.32
Chapter 2.1: Definition and classification of AKI
INTRODUCTION
AKI is one of a number of conditions that affect kidney
structure and function. AKI is defined by an abrupt decrease
in kidney function that includes, but is not limited to, ARF. It
is a broad clinical syndrome encompassing various etiologies,
including specific kidney diseases (e.g., acute interstitial
nephritis, acute glomerular and vasculitic renal diseases);
non-specific conditions (e.g, ischemia, toxic injury); as well
as extrarenal pathology (e.g., prerenal azotemia, and acute
postrenal obstructive nephropathy)—see Chapters 2.2 and
2.3 for further discussion. More than one of these conditions
may coexist in the same patient and, more importantly,
epidemiological evidence supports the notion that even mild,
reversible AKI has important clinical consequences, including
increased risk of death.2,5 Thus, AKI can be thought of more
like acute lung injury or acute coronary syndrome.
Furthermore, because the manifestations and clinical con-
sequences of AKI can be quite similar (even indistinguish-
able) regardless of whether the etiology is predominantly
within the kidney or predominantly from outside stresses on
the kidney, the syndrome of AKI encompasses both direct
injury to the kidney as well as acute impairment of function.
Since treatments of AKI are dependent to a large degree on
the underlying etiology, this guideline will focus on specific
diagnostic approaches. However, since general therapeutic
and monitoring recommendations can be made regarding all
forms of AKI, our approach will be to begin with general
measures.
Definition and staging of AKI
AKI is common, harmful, and potentially treatable. Even
a minor acute reduction in kidney function has an adverse
prognosis. Early detection and treatment of AKI may
improve outcomes. Two similar definitions based on SCr
and urine output (RIFLE and AKIN) have been proposed and
validated. There is a need for a single definition for practice,
research, and public health.
2.1.1: AKI is defined as any of the following (Not Graded):
K Increase in SCr by X0.3mg/dl (X26.5 lmol/l)
within 48 hours; or
K Increase in SCr to X1.5 times baseline, which
is known or presumed to have occurred within
the prior 7 days; or
K Urine volume o0.5ml/kg/h for 6 hours.
2.1.2: AKI is staged for severity according to the following
criteria (Table 2). (Not Graded)
2.1.3: The cause of AKI should be determined whenever
possible. (Not Graded)
RATIONALE
Conditions affecting kidney structure and function can be
considered acute or chronic, depending on their duration.
AKI is one of a number of acute kidney diseases and
disorders (AKD), and can occur with or without other acute
or chronic kidney diseases and disorders (Figure 2). Whereas
CKD has a well-established conceptual model and definition
that has been useful in clinical medicine, research, and public
health,42–44 the definition for AKI is evolving, and the
concept of AKD is relatively new. An operational definition
of AKD for use in the diagnostic approach to alterations
in kidney function and structure is included in Chapter 2.5,
with further description in Appendix B.
The conceptual model of AKI (Figure 3) is analogous to
the conceptual model of CKD, and is also applicable to
AKD.42,45 Circles on the horizontal axis depict stages in the
development (left to right) and recovery (right to left) of
AKI. AKI (in red) is defined as reduction in kidney function,
including decreased GFR and kidney failure. The criteria for
the diagnosis of AKI and the stage of severity of AKI are
based on changes in SCr and urine output as depicted in the
triangle above the circles. Kidney failure is a stage of AKI
highlighted here because of its clinical importance. Kidney
failure is defined as a GFR o15ml/min per 1.73 m2 body
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Table 2 | Staging of AKI
Stage Serum creatinine Urine output
1 1.5–1.9 times baseline
OR
X0.3mg/dl (X26.5mmol/l) increase
o0.5ml/kg/h for
6–12 hours
2 2.0–2.9 times baseline o0.5ml/kg/h for
X12 hours
3 3.0 times baseline
OR
Increase in serum creatinine to
X4.0mg/dl (X353.6mmol/l)
OR
Initiation of renal replacement therapy
OR, In patients o18 years, decrease in
eGFR to o35ml/min per 1.73 m2
o0.3ml/kg/h for
X24 hours
OR
Anuria for X12 hours
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surface area, or requirement for RRT, although it is
recognized that RRTmay be required earlier in the evolution
of AKI. Further description is included in Chapter 2.5 and
Appendix A.
It is widely accepted that GFR is the most useful overall
index of kidney function in health and disease, and changes
in SCr and urine output are surrogates for changes in GFR. In
clinical practice, an abrupt decline in GFR is assessed from an
increase in SCr or oliguria. Recognizing the limitations of the
use of a decrease in kidney function for the early detection
and accurate estimation of renal injury (see below), there is a
broad consensus that, while more sensitive and specific
biomarkers are needed, changes in SCr and/or urine output
form the basis of all diagnostic criteria for AKI. The first
international interdisciplinary consensus criteria for diag-
nosis of AKI were the RIFLE criteria32 proposed by the
ADQI. Modifications to these criteria have been proposed in
order to better account for pediatric populations (pRIFLE)32
and for small changes in SCr not captured by RIFLE (AKIN
criteria).23 Recommendations 2.1.1 and 2.1.2 represent the
combination of RIFLE and AKIN criteria (Table 3).
Existing evidence supports the validity of both RIFLE and
AKIN criteria to identify groups of hospitalized patients with
increased risk of death and/or need for RRT.2,5,25,28–30
Epidemiological studies, many multicentered, collectively
enrolling more than 500 000 subjects have been used to
establish RIFLE and/or AKIN criteria as valid methods to
diagnose and stage AKI. Recently, Joannidis et al.29 directly
compared RIFLE criteria with and without the AKIN
modification. While AKI classified by either criteria were
associated with a similarly increased hospital mortality, the
two criteria identified somewhat different patients. The
original RIFLE criteria failed to detect 9% of cases that were
detected by AKIN criteria. However, the AKIN criteria missed
26.9% of cases detected by RIFLE. Examination of the cases
missed by either criteria (Table 4) shows that cases identified
by AKIN but missed by RIFLE were almost exclusively Stage 1
(90.7%), while cases missed by AKIN but identified by RIFLE
included 30% with RIFLE-I and 18% RIFLE-F; furthermore,
these cases had hospital mortality similar to cases identified
by both criteria (37% for I and 41% for F). However, cases
missed by RIFLE but identified as Stage 1 by AKIN also had
hospital mortality rates nearly twice that of patients who had
no evidence of AKI by either criteria (25% vs. 13%). These
data provide strong rationale for use of both RIFLE and
AKIN criteria to identify patients with AKI.
Staging of AKI (Recommendation 2.1.2) is appropriate
because, with increased stage of AKI, the risk for death and
need for RRT increases.2,5,25,28–31 Furthermore, there is now
accumulating evidence of long-term risk of subsequent
development of cardiovascular disease or CKD and mortality,
even after apparent resolution of AKI.47–49
For staging purposes, patients should be staged accord-
ing to the criteria that give them the highest stage. Thus
when creatinine and urine output map to different stages,
AKIAKD CKD
Figure 2 |Overview of AKI, CKD, and AKD. Overlapping ovals
show the relationships among AKI, AKD, and CKD. AKI is a subset
of AKD. Both AKI and AKD without AKI can be superimposed
upon CKD. Individuals without AKI, AKD, or CKD have no known
kidney disease (NKD), not shown here. AKD, acute kidney diseases
and disorders; AKI, acute kidney injury; CKD, chronic kidney
disease.
Death
Complications
Normal Increased
risk
Antecedents
Intermediate Stage
AKI
Outcomes
Damage ↓
Stages defined by
creatinine and
urine output
are surrogates
Markers such
as NGAL, KIM-1,
and IL-18 are
surrogates
GFR
Damage
Kidney
failureGFR
Figure 3 |Conceptual model for AKI. Red circles represent stages of AKI. Yellow circles represent potential antecedents of AKI, and the
pink circle represents an intermediate stage (not yet defined). Thick arrows between circles represent risk factors associated with the
initiation and progression of disease that can be affected or detected by interventions. Purple circles represent outcomes of AKI.
‘‘Complications’’ refers to all complications of AKI, including efforts at prevention and treatment, and complications in other organ systems.
AKI, acute kidney injury; GFR, glomerular filtration rate. Adapted from Murray PT, Devarajan P, Levey AS, et al. A framework and key research
questions in AKI diagnosis and staging in different environments. Clin J Am Soc Nephrol 2008; 3: 864–868 with permission from American
Society of Nephrology45 conveyed through Copyright Clearance Center, Inc.; accessed http://cjasn.asnjournals.org/content/3/3/864.full
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the patient is staged according to the highest (worst) stage.
The changes in GFR that were published with the original
RIFLE criteria do not correspond precisely to changes in SCr.
As SCr is measured and GFR can only be estimated,
creatinine criteria should be used along with urine output
for the diagnosis (and staging) of AKI. One additional change
in the criteria was made for the sake of clarity and simplicity.
For patients reaching Stage 3 by SCr 44.0mg/dl
(4354 mmol/l), rather than require an acute increase of
X0.5mg/dl (X44mmol/l) over an unspecified time period, we
instead require that the patient first achieve the creatinine-
based change specified in the definition (either X0.3mg/dl
[X26.5mmol/l] within a 48-hour time window or an increase
ofX1.5 times baseline). This change brings the definition and
staging criteria to greater parity and simplifies the criteria.
Recommendation 2.1.2 is based on the RIFLE and AKIN
criteria that were developed for average-sized adults. The
creatinine change–based definitions include an auto-
matic Stage 3 classification for patients who develop SCr
44.0mg/dl (4354 mmol/l) (provided that they first satisfy
the definition of AKI in Recommendation 2.1.1). This is
problematic for smaller pediatric patients, including infants
and children with low muscle mass who may not be able to
achieve a SCr of 4.0mg/dl (354 mmol/l). Thus, the pediatric-
modified RIFLE AKI criteria32 were developed using a change
in estimated creatinine clearance (eCrCl) based on the
Schwartz formula. In pRIFLE, patients automatically reach
Stage 3 if they develop an eCrCl o35ml/min per 1.73 m2.
However, with this automatic pRIFLE threshold, the SCr
change based AKI definition (recommendation 2.1.1) is
applicable to pediatric patients, including an increase of
0.3mg/dl (26.5 mmol/l) SCr.32
There are important limitations to these recommenda-
tions, including imprecise determination of risk (see Chapter
2.2) and incomplete epidemiology of AKI, especially outside
the ICU. Clinical judgment is required in order to determine
if patients seeming to meet criteria do, in fact, have disease, as
well as to determine if patients are likely to have AKI even if
incomplete clinical data are available to apply the diagnostic
criteria. The application of the diagnostic and staging criteria
Table 3 | Comparison of RIFLE and AKIN criteria for diagnosis and classification of AKI
AKI staging
Urine output
RIFLE
Serum creatinine (common to both) Class Serum creatinine or GFR
Stage 1 Increase of more than or equal to 0.3mg/dl
(X26.5 mmol/l) or increase to more than or equal to
150% to 200% (1.5- to 2-fold) from baseline
Less than 0.5ml/kg/h for
more than 6 hours
Risk Increase in serum creatinine  1.5 or GFR
decrease 425%
Stage 2 Increased to more than 200% to 300%
(42- to 3-fold) from baseline
Less than 0.5ml/kg per hour
for more than 12 hours
Injury Serum creatinine  2 or GFR decreased
450%
Stage 3 Increased to more than 300% (43-fold)
from baseline, or more than or equal to 4.0mg/dl
(X354mmol/l) with an acute increase of at least
0.5mg/dl (44mmol/l) or on RRT
Less than 0.3ml/kg/h for
24 hours or anuria for
12 hours
Failure Serum creatinine  3, or serum creatinine
44mg/dl (4354mmol/l) with an acute
rise 40.5mg/dl (444mmol/l) or GFR
decreased 475%
Loss Persistent acute renal failure=complete
loss of kidney function 44 weeks
End-stage kidney
disease
ESRD 43 months
Note: For conversion of creatinine expressed in SI units to mg/dl, divide by 88.4. For both AKIN stage and RIFLE criteria, only one criterion (creatinine rise or urine output
decline) needs to be fulfilled. Class is based on the worst of either GFR or urine output criteria. GFR decrease is calculated from the increase in serum creatinine above
baseline. For AKIN, the increase in creatinine must occur in o48 hours. For RIFLE, AKI should be both abrupt (within 1–7 days) and sustained (more than 24 hours). When
baseline creatinine is elevated, an abrupt rise of at least 0.5mg/dl (44 mmol/l) to44mg/dl (4354 mmol/l) is sufficient for RIFLE class Failure (modified from Mehta et al.23 and
the report of the Acute Dialysis Quality Initiative consortium22).
AKI, acute kidney injury; AKIN, Acute Kidney Injury Network; ESRD, end-stage renal disease; GFR, glomerular filtration rate; RIFLE, risk, injury, failure, loss, and end stage; RRT,
renal replacement therapy. Reprinted from Endre ZH. Acute kidney injury: definitions and new paradigms. Adv Chronic Kidney Dis 2008; 15: 213–221 with permission from
National Kidney Foundation46; accessed http://www.ackdjournal.org/article/S1548-5595(08)00049-9/fulltext
Table 4 | Cross-tabulation of patients classified by RIFLE vs. AKIN
RIFLE
AKIN Non-AKI Risk Injury Failure Total (AKIN)
Non-AKI n* 8759 (12.9%) 781 (27.7%) 452 (37.4%) 271 (41.3%) 10 263 (15.9%)
Stage1 n* 457 (25.2%) 282 (33.0%) 243 (44.0%) 95 (60.0%) 1077 (34.5%)
Stage 2 n* 36 (30.6%) 21 (47.6%) 885 (25.9%) 91 (54.9) 1033 (29.0%)
Stage 3 n* 11 (18.2%) 8 (12.5%) 16 (62.5%) 1948 (41.3) 1983 (41.2%)
Total (RIFLE) n* 9263 (13.6%) 1092 (29.2%) 1596 (32.3%) 2405 (42.6%) 14 356 (21.7%)
*Number of patients classified into the respective stages of AKI by AKIN or RIFLE are cross-tabulated against each other. Hospital mortality of each group is given in
parentheses. Shaded fields denote patients assigned to the same degree of AKI by both classification systems.
AKI, acute kidney injury; AKIN, Acute Kidney Injury Network; RIFLE, risk, injury, failure, loss, and end stage. With kind permission from Springer Science+Business Media:
Intensive Care Med. Acute kidney injury in critically ill patients classified by AKIN versus RIFLE using the SAPS 3 database. 35 (2009): 1692–1702. Joannidis M, Metnitz B,
Bauer P et al.29; accessed http://www.springerlink.com/content/r177337030550120/
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is discussed in greater detail, along with specific examples in
Chapter 2.4.
The use of urine output criteria for diagnosis and staging
has been less well validated and in individual patients
the need for clinical judgment regarding the effects of drugs
(e.g., angiotensin-converting enzyme inhibitors [ACE-I]),
fluid balance, and other factors must be included. For very
obese patients, urine output criteria for AKI may include
some patients with normal urine output. However, these
recommendations serve as the starting point for further
evaluation, possibly involving subspecialists, for a group of
patients recognized to be at increased risk.
Finally, it is axiomatic that patients always be managed
according to the cause of their disease, and thus it is
important to determine the cause of AKI whenever possible.
In particular, patients with decreased kidney perfusion, acute
glomerulonephritis, vasculitis, interstitial nephritis, throm-
botic microangiopathy, and urinary tract obstruction require
immediate diagnosis and specific therapeutic intervention, in
addition to the general recommendations for AKI in the
remainder of this guideline (Table 5).
It is recognized that it is frequently not possible to deter-
mine the cause, and often the exact cause does not dictate a
specific therapy. However, the syndrome of AKI includes
some patients with specific kidney diseases (e.g., glome-
rulonephritis) for which a specific treatment is available. As
such, it is always necessary to search for the underlying cause
of AKI (see Chapter 2.3).
Research Recommendations
K The role of biomarkers other than SCr in the early
diagnosis, differential diagnosis, and prognosis of AKI
patients should be explored. Some important areas in
which to focus include:
J Early detection where the gold standard is AKI by
clinical diagnosis after the fact and the biomarker is
compared to existing markers (SCr and urine
output) at the time of presentation.
J Prognosis where a biomarker is used to predict risk
for AKI or risk for progression of AKI.
J Prognosis where a biomarker is used to predict
recovery after AKI vs. death or need for long-term RRT.
K The influence of urinary output criteria on AKI staging
needs to be further investigated. Influence of fluid
balance, percent volume overload, diuretic use, and
differing weights (actual, ideal body weight, lean body
mass) should be considered. Also, it is currently not
known how urine volume criteria should be applied (e.g.,
average vs. persistent reduction for the period specified).
K The influence of SCr or eGFR criteria on AKI staging
needs to be further investigated. The use of different
relative and absolute SCr increments or eGFR decrements
at different time points and with differently ascertained
baseline values requires further exploration and valida-
tion in various populations.
SUPPLEMENTARY MATERIAL
Appendix A: Background.
Appendix B: Diagnostic Approach to Alterations in Kidney Function
and Structure.
Supplementary material is linked to the online version of the paper at
http://www.kdigo.org/clinical_practice_guidelines/AKI.php
Table 5 | Causes of AKI and diagnostic tests
Selected causes of AKI requiring
immediate diagnosis and specific
therapies Recommended diagnostic tests
Decreased kidney perfusion Volume status and urinary
diagnostic indices
Acute glomerulonephritis, vasculitis,
interstitial nephritis, thrombotic
microangiopathy
Urine sediment examination,
serologic testing and
hematologic testing
Urinary tract obstruction Kidney ultrasound
AKI, acute kidney injury.
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Chapter 2.2: Risk assessment
The kidney is a fairly robust organ that can tolerate exposure to
several insults without suffering significant structural or
functional change. For this reason, any acute change in kidney
function often indicates severe systemic derangement and
predicts a poor prognosis. Risk for AKI is increased by exposure
to factors that cause AKI or the presence of factors that increase
susceptibility to AKI. Factors that determine susceptibility of the
kidneys to injury include dehydration, certain demographic
characteristics and genetic predispositions, acute and chronic
comorbidities, and treatments. It is the interaction between
susceptibility and the type and extent of exposure to insults that
determines the risk of occurrence of AKI.
Understanding individual ‘‘risk factors’’ may help in
preventing AKI. This is particularly gratifying in the hospital
setting, where the patient’s susceptibility can be assessed
before certain exposures as surgery or administration of
potentially nephrotoxic agents. Accordingly, some suscept-
ibility factors may be modified, and contemplated exposures
avoided or tailored to reduce the risk of AKI.
Risk assessment in community-acquired AKI is different
from hospital-acquired AKI, for two main reasons: i) Available
evidence on risk factors is largely derived from hospital data and
extrapolation to the community setting is questionable. ii) The
opportunity to intervene, prior to exposure, is quite limited.
Most patients are seen only after having suffered an exposure
(trauma, infection, poisonous plant, or animal). However, there
is still room to assess such patients, albeit after exposure, in
order to identify those who are more likely to develop AKI,
thereby requiring closer monitoring and general supportive
measures. It may also be helpful to identify such patients in
order to avoid additional injury. A more complete discussion of
the approach to identification and management of risk for AKI
is provided in Appendices C and D.
2.2.1: We recommend that patients be stratified for risk of AKI
according to their susceptibilities and exposures. (1B)
2.2.2: Manage patients according to their susceptibilities and
exposures to reduce the risk of AKI (see relevant
guideline sections). (Not Graded)
2.2.3: Test patients at increased risk for AKI with measure-
ments of SCr and urine output to detect AKI. (Not
Graded) Individualize frequency and duration of
monitoring based on patient risk and clinical course.
(Not Graded)
RATIONALE
There are many types of exposures that may cause AKI
(Table 6) and these are discussed in detail in Appendix C.
However, the chances of developing AKI after exposure to the
same insult differ among different individuals. This is
attributed to a number of susceptibility factors which vary
widely from individual to individual. Our understanding of
susceptibility factors (Table 6) is based on many observa-
tional studies that address different settings with regards to
the type, severity, duration, and multiplicity of insults. While
this heterogeneity provides insight into some susceptibility
factors that are common across various populations, the
generalizability of results from one particular setting to the
next is uncertain.
The course and outcome of AKI are modified by other
factors, but since these are manifested within the context of
actual disease, they must be categorized as ‘‘prognostic’’
rather than ‘‘risk’’ factors, hence being discussed separately in
Appendix D. Lastly, the fact that some 30% of patients who
recover from AKI remain at increased risk of CKD,
cardiovascular disease, and death calls for the identification
of the risk factors that can identify such patients in the hopes
of providing them with timely preventive measures.50–52
Finally, it is important to screen patients who have
undergone an exposure (e.g., sepsis, trauma) and to continue
monitor high-risk patients until the risk has subsided. Exact
intervals for checking SCr and in which individuals to
monitor urine output remain matters of clinical judgment;
however, as a general rule, high risk in-patients should have
SCr measured at least daily and more frequently after an
exposure, and critically ill patients should have urine output
monitoring. This will necessitate urinary bladder catheteriza-
tion in many cases, and the risks of infection should also be
considered in the monitoring plan.
A recent clinical practice assessment in the UK concluded
that only 50% of patients with AKI were considered to have
received a ‘‘good’’ overall standard of care. This figure fell to
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Table 6 | Causes of AKI: exposures and susceptibilities for
non-specific AKI
Exposures Susceptibilities
Sepsis Dehydration or volume depletion
Critical illness Advanced age
Circulatory shock Female gender
Burns Black race
Trauma CKD
Cardiac surgery (especially
with CPB)
Chronic diseases (heart, lung, liver)
Major noncardiac surgery Diabetes mellitus
Nephrotoxic drugs Cancer
Radiocontrast agents Anemia
Poisonous plants and animals
CKD, chronic kidney disease; CPB, cardiopulmonary bypass.
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just over 30% if AKI developed during a hospital admission
rather than being diagnosed before admission.53 The authors
also felt that there was an unacceptable delay in recognizing
AKI in 43% of those that developed the condition after
admission, and that in a fifth of such patients its develop-
ment was predictable and avoidable. Their recommendations
were simple: risk assessment for AKI as part of the initial
evaluation of emergency admissions, along with appropriate
serum biochemistry on admission and at frequent intervals
thereafter.53
RESEARCH RECOMMENDATIONS
K Better delineation of risk for hospital- and community-
acquired AKI is needed.
K Better delineation of the effects of age on the risk for AKI
is needed.
K Studies are needed to develop and validate scoring systems
for AKI risk prediction in various settings, in addition to
cardiac surgery and exposure to radiocontrast material.
K Genome-wide association studies are needed to deter-
mine risk of AKI in different hospital settings and with
respect to long-term outcomes.
K Studies are needed on risk factors for the development of,
recovery from, and long-term outcomes of community-
acquired AKI, including sepsis, trauma, tropical infec-
tions, snake bites, and ingestion of toxic plants, etc.
SUPPLEMENTARY MATERIAL
Appendix C: Risk Determination.
Appendix D: Evaluation and General Management Guidelines for
Patients with AKI.
Supplementary material is linked to the online version of the paper at
http://www.kdigo.org/clinical_practice_guidelines/AKI.php
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Chapter 2.3: Evaluation and general management of
patients with and at risk for AKI
Given that AKI is associated with significant morbidity and
mortality, and because no specific treatment is available to
reverse AKI, early recognition and management is para-
mount. Indeed, recognition of patients at risk for AKI, or
with possible AKI but prior to clinical manifestations, is
likely to result in better outcomes than treating only
established AKI. Chapter 2.2 introduced the approach to
risk assessment with further detail provided in Appendix C.
This chapter will concern itself with the evaluation
and general management of patients with, or even at risk
for, AKI. Further detail is provided in Appendix D. We
highlight the importance of beginning management at the
earliest point in the development of AKI—in patients with
suspected AKI or even in those at increased risk who have
been exposed to the various factors discussed in Chapters 2.2
and Appendix C.
Although much of the remaining chapters in this guide-
line pertain to management of specific aspects of AKI, there
are general management principles that are common to all
patients and these will be discussed here and further
expounded upon in Appendix D. Treatment goals in patients
with AKI include both reducing kidney injury and complica-
tions related to decreased kidney function.
2.3.1: Evaluate patients with AKI promptly to determine
the cause, with special attention to reversible
causes. (Not Graded)
2.3.2: Monitor patients with AKI with measurements of
SCr and urine output to stage the severity,
according to Recommendation 2.1.2. (Not Graded)
2.3.3: Manage patients with AKI according to the stage
(see Figure 4) and cause. (Not Graded)
2.3.4: Evaluate patients 3 months after AKI for resolu-
tion, new onset, or worsening of pre-existing CKD.
(Not Graded)
K If patients have CKD, manage these patients as
detailed in the KDOQI CKD Guideline (Guide-
lines 7–15). (Not Graded)
K If patients do not have CKD, consider them to be
at increased risk for CKD and care for them as
detailed in the KDOQI CKD Guideline 3 for
patients at increased risk for CKD. (Not Graded)
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Figure 4 | Stage-based management of AKI. Shading of boxes indicates priority of action—solid shading indicates actions that are
equally appropriate at all stages whereas graded shading indicates increasing priority as intensity increases. AKI, acute kidney injury;
ICU, intensive-care unit.
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RATIONALE
As emphasized in Chapter 2.2, AKI is not a disease but
rather a clinical syndrome with multiple etiologies. While
much of the literature examining epidemiology and clinical
consequences of AKI appear to treat this syndrome as a
homogeneous disorder, the reality is that AKI is hetero-
geneous and often is the result of multiple insults. Figure 5
illustrates an approach to evaluation of AKI. Further
discussion of evaluation in clinical practice is provided in
Appendix D.
The clinical evaluation of AKI includes a careful history
and physical examination. Drug history should include over-
the-counter formulations and herbal remedies or recreational
drugs. The social history should include exposure to tropical
diseases (e.g., malaria), waterways or sewage systems, and
exposure to rodents (e.g., leptospirosis, hantavirus). Physical
examination should include evaluation of fluid status, signs
for acute and chronic heart failure, infection, and sepsis.
Measurement of cardiac output, preload, preload respon-
siveness, and intra-abdominal pressure should be considered
Figure 5 | Evaluation of AKI according to the stage and cause.
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in the appropriate clinical context. Laboratory parameters—
including SCr, blood urea nitrogen (BUN), and electrolytes,
complete blood count and differential—should be obtained.
Urine analysis and microscopic examination as well as
urinary chemistries may be helpful in determining the
underlying cause of AKI. Imaging tests, especially ultrasound,
are important components of the evaluation for patients with
AKI. Finally, a number of biomarkers of functional change
and cellular damage are under evaluation for early diagnosis,
risk assessment for, and prognosis of AKI (see Appendix D
for detailed discussion).
Individualize frequency and duration of monitoring based
on patient risk, exposure and clinical course. Stage is a predictor
of the risk for mortality and decreased kidney function (see
Chapter 2.4). Dependent on the stage, the intensity of future
preventive measures and therapy should be performed.
Because the stage of AKI has clearly been shown to
correlate with short-term2,5,27,29 and even longer-term out-
comes,31 it is advisable to tailor management to AKI stage.
Figure 4 lists a set of actions that should be considered for
patients with AKI. Note that for patients at increased risk (see
Chapters 2.2 and 2.4), these actions actually begin even
before AKI is diagnosed.
Note that management and diagnostic steps are both
included in Figure 4. This is because response to therapy is an
important part of the diagnostic approach. There are few
specific tests to establish the etiology of AKI. However, a
patient’s response to treatment (e.g., discontinuation of a
possible nephrotoxic agent) provides important information
as to the diagnosis.
Nephrotoxic drugs account for some part of AKI in 20–30%
of patients. Often, agents like antimicrobials (e.g., aminoglyco-
sides, amphotericin) and radiocontrast are used in patients that
are already at high risk for AKI (e.g., critically ill patients with
sepsis). Thus, it is often difficult to discern exactly what
contribution these agents have on the overall course of AKI.
Nevertheless, it seems prudent to limit exposure to these agents
whenever possible and to weigh the risk of developing or
worsening AKI against the risk associated with not using the
agent. For example, when alternative therapies or diagnostic
approaches are available they should be considered.
In order to ensure adequate circulating blood volume, it is
sometimes necessary to obtain hemodynamic variables. Static
variables like central venous pressure are not nearly as useful
as dynamic variables, such as pulse-pressure variation,
inferior vena cava filling by ultrasound and echocardio-
graphic appearance of the heart (see also Appendix D).
Note that while the actions listed in Figure 4 provide
an overall starting point for stage-based evaluation and
management, they are neither complete not mandatory for
an individual patient. For example, the measurement of urine
output does not imply that the urinary bladder catheteriza-
tion is mandatory for all patients, and clinicians should
balance the risks of any procedures with the benefits.
Furthermore, clinicians must individualize care decisions
based on the totality of the clinical situation. However, it is
advisable to include AKI stage in these decisions.
The evaluation and management of patients with AKI
requires attention to cause and stage of AKI, as well as factors
that relate to further injury to the kidney, or complications
from decreased kidney function. Since AKI is a risk factor for
CKD, it is important to evaluate patients with AKI for new
onset or worsening of pre-existing CKD. If patients have
CKD, manage patients as detailed in the KDOQI CKD
Guideline (Guidelines 7–15). If patients do not have CKD,
consider them to be at increased risk for CKD and care for
them as detailed in the KDOQI CKD Guideline 3 for patients
at increased risk for CKD.
RESEARCH RECOMMENDATIONS
K Clinical research aimed at testing early management
strategies is urgently needed. Such trials should also
address the risks and benefits of commonly used fluid-
management strategies, including intravenous (i.v.) fluids
and diuretics.
K Methods to better assess fluid status in critically ill and
other hospitalized patients at risk for AKI are needed.
K Research is needed, with follow-up beyond hospital stay,
to better understand the clinical consequences of AKI in
patients with and without underlying CKD.
SUPPLEMENTARY MATERIAL
Appendix C: Risk Determination.
Appendix D: Evaluation and General Management Guidelines for
Patients with AKI.
Supplementary material is linked to the online version of the paper at
http://www.kdigo.org/clinical_practice_guidelines/AKI.php
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Chapter 2.4: Clinical applications
This chapter provides a detailed application of the AKI
definition and staging for clinical diagnosis and management.
The definitions and classification system discussed in
Chapter 2.1 can be used easily in many patients and requires
little clinical interpretation. However, in real time, clinicians
do not always have a complete dataset to work with
and individual patients present with unique histories. As
discussed in the previous chapter, it is difficult to distinguish
AKI from CKD in many cases. In addition, as many as
two-thirds of all cases of AKI begin prior to hospitali-
zation (community-acquired AKI). Therefore, clinicians
may be faced with patients in whom kidney function
is already decreased and, during the hospitalization,
improves rather than worsens. Finally, many patients
do not have a prior measurement of kidney function
available for comparison. This chapter provides detailed
examples of the application of these definitions to the clinical
setting.
Examples of application of AKI definitions
Table 7 illustrates a number of examples whereby patients
presenting with possible AKI can be diagnosed. Cases A-F
have a measurement of baseline SCr. To simplify decision-
making, baseline estimated glomerular filtration rate (eGFR)
exceeds 60ml/min per 1.73 m2 in these patients, so none has
pre-existing CKD. Cases A-F can all be diagnosed with AKI
by applying the first two criteria in Recommendation 2.1.1. (a
documented increase of at least 0.3mg/dl (426.5 mmol/l)
[within 48 hours or a 50% increase from presumed baseline).
Note that a patient can be diagnosed with AKI by fulfilling
either criterion 1 or 2 (or 3, urine output) and thus cases
B,C,D, and F all fulfill the definition of AKI. Note also that
patients may be diagnosed earlier using criterion 1 or 2. Early
diagnosis may improve outcome so it is advantageous to
diagnose patients as rapidly as possible. For example, case A
can be diagnosed with AKI on day 2 by the first criterion,
whereas the second criterion is not satisfied until day 3
(increase from 1.3 to 1.9). However, this is only true because
the episode of AKI began prior to medical attention, and thus
the day 1 SCr level was already increased. If creatinine
measurements had available with 48 hours prior to day 1 and
if this level had been at baseline (1.0mg/dl [88.4 mmol/l]), it
would have been possible to diagnose AKI on day 1 using the
second criterion.
Cases F-H do not have a baseline measurement of SCr
available. Elevated SCr (reduced eGFR) on day 1 of the
hospitalization is consistent with either CKD or AKD
without AKI. In Case F, baseline SCr can be inferred
to be below the day 1 value because of the subsequent
clinical course; thus, we can infer the patient has had an
episode of AKI. In case G, AKI can be diagnosed by
application of criterion 2, but the patient may have under-
lying CKD. Case H does not fulfill the definition for
AKI based on either criteria, and has either CKD or AKD
without AKI.
The example of Case A raises several important issues.
First, frequent monitoring of SCr in patients at increased risk
of AKI will significantly improve diagnostic time and
accuracy. If Case A had not presented to medical attention
(or if SCr had not been checked) until day 7, the case of AKI
would likely have been missed. Frequent measurement of SCr
in high-risk patients, or in patients in which AKI is suspected,
is therefore encouraged—see Chapter 2.3. The second issue
highlighted by Case A is the importance of baseline SCr
measurements. Had no baseline been available it would still
have been possible to diagnose AKI on day 3 (by either using
criterion 2 or by using criterion 1 and accepting the baseline
SCr as 1.3); however, not only would this have resulted in a
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Table 7 | AKI diagnosis
Serum creatinine mg/dl (lmol/l) Diagnosis AKI?
Criterion 1 Criterion 2
Case Baseline Day 1 Day 2 Day 3 Day 7 50% from baseline X0.3mg/dl (X26.5lmol/l) rise in p48 hours
A 1.0 (88) 1.3 (115) 1.5 (133) 2.0 (177) 1.0 (88) Yes Yes
B 1.0 (88) 1.1 (97) 1.2 (106) 1.4 (124) 1.0 (88) No Yes
C 0.4 (35) 0.5 (44) 0.6 (53) 0.7 (62) 0.4 (35) Yes No
D 1.0 (88) 1.1 (97) 1.2 (106) 1.3 (115) 1.5 (133) Yes No
E 1.0 (88) 1.3 (115) 1.5 (133) 1.8 (159) 2.2 (195) Yes Yes
F ? 3.0 (265) 2.6 (230) 2.2 (195) 1.0 (88) Yes No
G ? 1.8 (159) 2.0 (177) 2.2 (195) 1.6 (141) ? Yes
H ? 3.0 (265) 3.1 (274) 3.0 (265) 2.9 (256) ? No
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delay in diagnosis, it would have resulted in a delay in staging
(see Table 7). On day 7, it can be inferred that the patient’s
baseline was no higher than 1.0mg/dl (88 mmol/l) and thus
correct staging of Case A as Stage 2 (two-fold increase from
the reference SCr, see below and Table 7) on day 3 could have
been determined in retrospect. However, if a baseline SCr was
available to use as the reference, the correct stage could be
determined on day 3.
Case B illustrates why criterion 2 can detect cases of AKI
missed by criterion 1. It also clarifies why these cases are
unusual. Had the SCr increased to 1.5mg/dl (132.6 mmol/l)
as opposed to peaking at 1.4mg/dl (123.8 mmol/l), it would
have been picked up by criterion 1 as well. By contrast
Cases C, D, and even F illustrate how criterion 2 may
miss cases identified by criterion 1. Note that Case F can
only be diagnosed by inference. By day 7, it can be
inferred that the baseline was no higher than 1.0mg/dl
(88 mmol/l) and thus it can be determined that the patient
presented with AKI. However, if the baseline SCr could
be estimated it would be possible to make this inference as
early as day 1.
Estimating baseline SCr
Many patients will present with AKI without a reliable
baseline SCr on record. Baseline SCr can be estimated using
the Modification of Diet in Renal Disease (MDRD) Study
equation assuming that baseline eGFR is 75ml/min per 1.73
m2 (Table 9).22 This approach has been used in many, but not
all, studies of AKI epidemiology using RIFLE2,5,25,30–32,54–63
(see Table 8) and has recently been validated.64 Hence, most
current data concerning AKI defined by RIFLE criteria are
based on estimated baseline SCr for a large proportion of
patients.
Table 9 shows the range of estimated SCr obtained by
back-calculation for various age, sex, and race categories.
When the baseline SCr is unknown, an estimated SCr can be
used provided there is no evidence of CKD (see Appendix B).
Fortunately, when there is a history of CKD, a baseline SCr is
usually available. Unfortunately, many cases of CKD are not
identified, and thus estimating the baseline SCr may risk
labeling a patient with AKI when in reality the diagnosis was
unidentified CKD. As discussed further in Appendix B, it is
essential to evaluate a patient with presumed AKI for
Table 8 | Overview of the approaches to determine baseline SCr in the application of RIFLE classification in previous studies
Study
No. of pts
analyzed
Multi-/
single-center
Criteria
used Method to determine baseline SCr
%
recorded
%
estimated
Bagshaw25 120123 multi cr+uo estimated by MDRD formula 0 100
Ostermann30 41972 multi cr estimated by MDRD formula 0 100
Uchino5 20126 single cr retrieved from hospital database, or estimated by MDRD formula N/A N/A
Bell54 8152 single cr+uo retrieved from hospital database, or estimated by MDRD formula N/A N/A
Hoste2 5383 single cr+uo estimated by MDRD formula, or admission creatinine value,
whatever was lower
N/A N/A
Ali31 5321 multi cr retrieved from hospital database, or admission creatinine value 100 0
Cruz55 2164 multi cr+uo retrieved from hospital database, or estimated by MDRD formula 78 22
Perez-Valdivieso56 1008 single cr estimated by MDRD formula 0 100
Kuitunen57 813 single cr+uo preoperative value 100 0
Coca58 304 single cr the lowest s-creatinine value in the first 5 hospital days 100 0
Arnaoutakis59 267 single N/A N/A N/A N/A
Abosaif60 247 single cr+uo retrieved from hospital database, or admission creatinine value 100 0
Maccariello61 214 multi cr+uo retrieved from hospital database, or estimated by MDRD formula N/A N/A
Jenq62 134 single cr+uo admission creatinine value, or estimated by MDRD formula 90 10
cr, creatinine criteria; MDRD, Modification of Diet in Renal Disease; N/A, not available; pts, patients; SCr, serum creatinine; uo, urine output criteria.
Reprinted from Zavada J, Hoste E, Cartin-Ceba R et al. A comparison of three methods to estimate baseline creatinine for RIFLE classification. Nephrol Dial Transplant 2010;
25(12): 3911–3918 (Ref. 64) by permission from The European Renal Association-European Dialysis and Transplant Association; accessed http://ndt.oxfordjournals.org/content/
25/12/3911.long
Table 9 | Estimated baseline SCr
Age (years) Black males mg/dl (lmol/l) Other males mg/dl (lmol/l) Black females mg/dl (lmol/l) Other females mg/dl (lmol/l)
20–24 1.5 (133) 1.3 (115) 1.2 (106) 1.0 (88)
25–29 1.5 (133) 1.2 (106) 1.1 (97) 1.0 (88)
30–39 1.4 (124) 1.2 (106) 1.1 (97) 0.9 (80)
40–54 1.3 (115) 1.1 (97) 1.0 (88) 0.9 (80)
55–65 1.3 (115) 1.1 (97) 1.0 (88) 0.8 (71)
465 1.2 (106) 1.0 (88) 0.9 (80) 0.8 (71)
Estimated glomerular filtration rate=75 (ml/min per 1.73 m2)=186  (serum creatinine [SCr]) 1.154  (age) 0.203  (0.742 if female)  (1.210 if black)=exp(5.228 1.154
In [SCr])  0.203  In(age)  (0.299 if female) + (0.192 if black).
Reprinted from Bellomo R, Ronco C, Kellum JA et al. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the
Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8: R204-212 with permission from Bellomo R et al.22; accessed
http://ccforum.com/content/8/4/R204
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presence of CKD. Furthermore, CKD and AKI may coexist.
By using all available clinical data (laboratory, imaging,
history, and physical exam) it should be possible to arrive at
both an accurate diagnosis as well as an accurate estimate of
baseline SCr. Importantly, excluding some cases of hemo-
dilution secondary to massive fluid resuscitation (discussed
below), the lowest SCr obtained during a hospitalization
is usually equal to or greater than the baseline. This SCr
should be used to diagnose (and stage) AKI. For example, if
no baseline SCr was available in Case A, diagnosis of AKI
could be made using the MDRD estimated SCr (Table 9). If
Case A were a 70-year-old white female with no evidence or
history of CKD, the baseline SCr would be 0.8mg/dl
(71 mmol/l) and a diagnosis of AKI would be possible
even on day 1 (criterion 1, X50% increase from baseline).
However, if the patient was a 20-year-old black male, his
baseline SCr would be estimated at 1.5mg/dl (133 mmol/l).
Since his admission SCr is lower, this is assumed to be the
baseline SCr until day 7 when he returns to his true baseline,
and this value can be taken as the baseline. These dynamic
changes in interpretation are not seen in epidemiologic
studies, which are conducted when all the data are present,
but are common in clinical medicine. Note that the only
way to diagnose AKI (by SCr criteria) in Case H is to use an
estimated SCr.
Examples of application of AKI stages
Once a diagnosis of AKI has been made, the next step is to
stage it (Recommendation 2.1.2). Like diagnosis, staging
requires reference to a baseline SCr when SCr criteria are
used. This baseline becomes the reference SCr for staging
purposes. Table 10 shows the maximum stage for each
Case described in Table 7. Staging for Case A was already
mentioned. The maximum stage is 2 because reference SCr is
1.0mg/dl (88 mmol/l) and the maximum SCr is 2.0mg/dl
(177 mmol/l). Had the reference SCr been 0.6mg/dl (53 mmol/
l), the maximum stage would have been 3. Case F was staged
by using the lowest SCr (1.0mg/dl [88 mmol/l]) as the
reference. Of course, the actual baseline for this case might
have been lower but this would not affect the stage, since it is
already Stage 3. Note that if this patient was a 35-year-old
white male, his MDRD estimated baseline SCr would be
1.2mg/dl (106 mmol/l) (Table 9) and his initial stage on
admission (day 1) would be assumed to be 2. However, once
his SCr recovered to 1.0mg/dl (88 mmol/l) on day 7, it would
be possible to restage him as having had Stage 3. Once he has
recovered, there may be no difference between Stage 2 or 3 in
terms of his care plan. On the other hand, accurately staging
the severity of AKI may be important for intensity of follow-
up and future risk.
Note that Cases G and H can only be staged if the
reference SCr can be inferred. Case G may be as mild as stage
1 if the baseline is equal to the nadir SCr on day 7. On the
other hand, if this case were a 70-year-old white female with
no known evidence or history of CKD, the reference SCr
would be 0.8mg/dl (71 mmol/l) based on an estimated
baseline (Table 9). In this case, the severity on day 1 would
already be stage 2.
Urine output vs. SCr
Both urine output and SCr are used as measures of an acute
change in GFR. The theoretical advantage of urine output
over SCr is the speed of the response. For example, if GFR
were to suddenly fall to zero, a rise in SCr would not be
detectable for several hours. On the other hand, urine output
would be affected immediately. Less is known about the use
of urine output for diagnosis and staging compared to SCr,
since administrative databases usually do not capture urine
output (and frequently it is not even measured, especially
outside the ICU). However, studies using both SCr and urine
output to diagnose AKI show increased incidence, suggesting
that the use of SCr alone may miss many patients. The use
of urine output criteria (criterion 3) will also reduce the
number of cases where criterion 1 and criterion 2 are
discordant (cases B,C,D, and F in Table 7), as many of these
cases will be picked up by urine output criteria.
Timeframe for diagnosis and staging
The purpose of setting a timeframe for diagnosis of AKI is to
clarify the meaning of the word ‘‘acute’’. A disease process
that results in a change in SCr over many weeks is not AKI
(though it may still be an important clinical entity: see
Appendix B). For the purpose of this guideline, AKI is
defined in terms of a process that results in a 50% increase in
Table 10 | AKI staging
Serum creatinine mg/dl (lmol/l)
Case Baseline Day 1 Day 2 Day 3 Day 7 Reference creatinine Max AKI stage
A 1.0 (88) 1.3 (115) 1.5 (133) 2.0 (177) 1.0 (88) 1.0 (88) 2
B 1.0 (88) 1.1 (97) 1.2 (106) 1.4 (124) 1.0 (88) 1.0 (88) 1
C 0.4 (35) 0.5 (44) 0.6 (53) 0.7 (62) 0.4 (35) 0.4 (35) 1
D 1.0 (88) 1.1 (97) 1.2 (106) 1.3 (115) 1.5 (133) 1.0 (88) 1
E 1.0 (88) 1.3 (115) 1.5 (133) 1.8 (159) 2.2 (195) 1.0 (88) 2
F ? 3.0 (265) 2.6 (230) 2.2 (195) 1.0 (88) 1.0 (88) 3
G ? 1.8 (159) 2.0 (177) 2.2 (195) 1.6 (141) ? X1
H ? 3.0 (265) 3.1 (274) 3.0 (265) 2.9 (256) ? ?
AKI, acute kidney injury.
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SCr within 1 week or a 0.3mg/dl (26.5 mmol/l) increase
within 48 hours (Recommendation 2.1.1). Importantly, there
is no stipulation as to when the 1-week or 48-hour time
periods can occur. It is stated unequivocally that it does not
need to be the first week or 48 hours of a hospital or ICU stay.
Neither does the time window refer to duration of the
inciting event. For example, a patient may have a 2-week
course of sepsis but only develop AKI in the second week.
Importantly, the 1-week or 48-hour timeframe is for
diagnosis of AKI, not staging. A patient can be staged over
the entire episode of AKI such that, if a patient develops a
50% increase in SCr in 5 days but ultimately has a three-fold
increase over 3 weeks, he or she would be diagnosed with AKI
and ultimately staged as Stage 3.
As with any clinical criteria, the timeframe for AKI is
somewhat arbitrary. For example, a disease process that
results in a 50% increase in SCr over 2 weeks would not fulfill
diagnostic criteria for AKI even if it ultimately resulted in
complete loss of kidney function. Similarly, a slow process
that resulted in a steady rise in SCr over 2 weeks, and then a
sudden increase of 0.3mg/dl (26.5 mmol/l) in a 48-hour
period, would be classified as AKI. Such are the inevitable
vagaries of any disease classification. However, one scenario
deserves specific mention, and that is the case of the patient
with an increased SCr at presentation. As already discussed,
the diagnosis of AKI requires a second SCr value for
comparison. This SCr could be a second measured SCr
obtained within 48 hours, and if it is X0.3mg/dl
(X26.5 mmol/l) greater than the first SCr, AKI can be
diagnosed. Alternatively, the second SCr can be a baseline
value that was obtained previously or estimated from the
MDRD equation (see Table 9). However, this poses two
dilemmas. First, how far back can a baseline value be
retrieved and still expected to be ‘‘valid’’; second, how can
we infer acuity when we are seeing the patient for the first
time?
Both of these problems will require an integrated
approach as well as clinical judgment. In general, it is
reasonable in patients without CKD to assume that SCr
will be stable over several months or even years, so that
a SCr obtained 6 months or even 1 year previously would
reasonable reflect the patient’s premorbid baseline. However,
in a patient with CKD and a slow increasing SCr over several
months, it may be necessary to extrapolate the baseline SCr
based on prior data. In terms of inferring acuity it is most
reasonable to determine the course of the disease process
thought to be causing the episode of AKI. For example, for a
patient with a 5-day history of fever and cough, and chest
radiograph showing an infiltrate, it would be reasonable to
infer that the clinical condition is acute. If SCr is found to be
X50% increased from baseline, this fits the definition of AKI.
Conversely, a patient presenting with an increased SCr in the
absence of any acute disease or nephrotoxic exposure will
require evidence of an acute process before a diagnosis can be
made. Evidence that the SCr is changing is helpful in
establishing acuity.
Clinical judgment
While the definitions and classification system discussed in
Chapter 2.1 provide a framework for the clinical diagnosis of
AKI, they should not be interpreted to replace or to exclude
clinical judgment. While the vast majority of cases will
fit both AKI diagnostic criteria as well as clinical judgment,
AKI is still a clinical diagnosis—not all cases of AKI will fit
within the proposed definition and not all cases fitting the
definition should be diagnosed as AKI. However, exceptions
should be very rare.
Pseudo-AKI. As with other clinical diagnoses defined by
laboratory results (e.g., hyponatremia), the clinician must be
cautious to interpret laboratory data in the clinical context.
The most obvious example is with laboratory errors or errors
in reporting. Erroneous laboratory values should obviously
not be used to diagnose disease and suspicious lab results
should always be repeated. Another example is when two SCr
measurements are obtained by different laboratories. While
the coefficient of variation for SCr is very small (o5%) by
various clinical testing methods, variation (bias) from one
laboratory to the next may be considerably higher, although
it is unlikely to approach 50%. Given that the SCr definition
of AKI always uses at least two values, the variation and bias
between each measure is further magnified—the coefficient
of variation for comparison of two lab tests is equal to the
square root of the sum of each coefficient squared. Although
the international standardization of SCr measurements will
largely eliminate interlaboratory bias in the future, care is
needed in interpreting lab values obtained from different
labs. Furthermore, daily variation in SCr due to differences in
diet and activity may be as great as 10%. Finally, endogenous
chromogens (e.g., bilirubin, ascorbic acid, uric acid) and
exogenous chromogens and drugs (e.g., cephalosporins,
trimethoprim, cimetidine) may interfere with the creatinine
assay. The cumulative effect of these various factors
influencing precision, bias, and biological variation may
approach the level at which it could impact the diagnosis of
AKI. A similar problem exists with urine output. Particularly
outside the ICU, urine output is not often reported and urine
collections may be inaccurate, especially in noncatheterized
patients. Finally, as discussed in Chapter 2.1, a weight-based
criterion for urine output will mean that some very obese
patients will fulfill the definition of AKI without any kidney
abnormality. Clinical judgment should always be exercised in
interpreting such data.
Atypical AKI. A complementary problem to pseudo-AKI is
the situation where a case of AKI fails to meet the definition.
These cases should be distinguished from conditions in which
data are simply missing (discussed above) and refer to
situations in which existing data are unreliable. For example,
a patient might receive very large quantities of intravascular
fluids such that SCr is falsely lowered.65 Similarly, massive
blood transfusions will result in the SCr more closely
reflecting the kidney function of the blood donors than the
patient. It is unusual for these cases not to result in oliguria
and, thus, most patients will be diagnosed with AKI even if
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SCr is not increased. Nevertheless, the clinician should
be cognizant of possibility that SCr may be falsely lowered
by large-volume fluid resuscitation or transfusion; thus, a
normal value may not rule out AKI. Changes in creatinine
production are also well known in conditions such as muscle
breakdown where production increases and in muscle
wasting (including advanced liver disease) where production
is decreased. Creatinine production may also be decreased in
sepsis66 possibly due to decreased muscle perfusion.
SUPPLEMENTARY MATERIAL
Appendix B: Diagnostic Approach to Alterations in Kidney Function
and Structure.
Supplementary material is linked to the online version of the paper at
http://www.kdigo.org/clinical_practice_guidelines/AKI.php
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Chapter 2.5: Diagnostic approach to alterations in
kidney function and structure
Definitions of AKI, CKD and AKD
AKI and CKD were defined by separate Work Groups
according to different criteria. The definition for each is
based on alterations in kidney function or structure. AKI and
CKD have many causes which may lead to alterations of
kidney function and structure that do not meet the criteria
for the definition of either AKI or CKD, yet patients with
these diseases and disorders may need medical attention to
restore kidney function and reverse damage to kidney
structure to avoid adverse outcomes. A uniform and
systematic nomenclature could enhance understanding and
communication about these diseases and disorders, and lead
to improved medical care, research, and public health. For
these reasons, the Work Group proposed an operational
definition for AKD to provide an integrated clinical approach
to patients with abnormalities of kidney function and
structure.
Table 11 compares the definitions for AKI, CKD, and
AKD. We have also included an operational definition of ‘‘no
known kidney disease’’ (NKD) for those who do not meet
these criteria, with the understanding that clinical judgment
is required to determine the extent of the evaluation that is
necessary to assess kidney function and structure. In the
following sections, we will elaborate on each component of
these definitions.
GFR and SCr
CKD, AKD, and AKI are defined by parameters expressing
the level of kidney function. Table 12 gives examples of each
condition based on GFR and different magnitudes of increase
in SCr.
To illustrate the relationship of changes in SCr to changes
in eGFR, we simulated changes in eGFR that would result
from changes in SCr corresponding to the KDIGO definition
of AKI in the Chronic Kidney Disease Epidemiology
Collaboration cohort.67,68 Figure 6 shows the relationship
of these changes in eGFR to the definition and stages of AKI.
Not all patients with AKI would meet the eGFR criteria for
the definition of AKD.
GFR/SCr algorithm
Figure 7 provides a diagnostic algorithm based on a
sequential approach through three questions: i) Is GFR
decreased or is SCr increased (according to the criteria in
Table 12)?; ii) Is SCr increasing or GFR decreasing (according
to the criteria in Table 12)?; and iii) Does the decrease in GFR
or increase in SCr resolve within 3 months? Based on a ‘‘yes’’
or ‘‘no’’ response to these three sequential questions, all
combinations of AKI, AKD, and CKD can be identified. In
this section, we review the algorithm and illustrate its use
for classification of patients with acute and chronic kidney
disease in two previously reported cohorts.
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Table 11 | Definitions of AKI, CKD, and AKD
Functional criteria Structural criteria
AKI Increase in SCr by 50% within 7 days, OR
Increase in SCr by 0.3mg/dl (26.5mmol/l)
within 2 days, OR
Oliguria
No criteria
CKD GFR o60ml/min per 1.73m2 for
43 months
Kidney damage
for 43 months
AKD AKI, OR
GFR o60ml/min per 1.73m2 for
o3 months, OR
Decrease in GFR by X35% or increase
in SCr by 450% for o3 months
Kidney damage
for o3 months
NKD GFR X60ml/min per 1.73m2
Stable SCr
No damage
GFR assessed from measured or estimated GFR. Estimated GFR does not reflect
measured GFR in AKI as accurately as in CKD. Kidney damage assessed by pathology,
urine or blood markers, imaging, and—for CKD—presence of a kidney transplant. NKD
indicates no functional or structural criteria according to the definitions for AKI, AKD,
or CKD. Clinical judgment is required for individual patient decision-making regarding
the extent of evaluation that is necessary to assess kidney function and structure.
AKD, acute kidney diseases and disorders; AKI, acute kidney injury; CKD, chronic
kidney disease; GFR, glomerular filtration rate; NKD, no known kidney disease;
SCr, serum creatinine.
Table 12 | Examples of AKI, CKD, and AKD based on GFR and
increases in SCr
Baseline GFR
(ml/min per
1.73 m2)
Increase in
SCr during
7 consecutive days
GFR during
next
3 months Diagnosis
460 41.5 NA AKI
460 o1.5 o60 AKD without AKI
460 o1.5 460 NKD
Baseline GFR
(ml/min per
1.73 m2)
Change in SCr
during next
7 days
GFR during
next
3 months Diagnosis
o60 41.5 NA AKI + CKD
o60 o1.5 435% decrease AKD without
AKI + CKD
o60 o1.5 o35% decrease CKD
GFR assessed from measured or estimated GFR. Estimated GFR does not reflect
measured GFR in AKI as accurately as in CKD.
AKD, acute kidney diseases and disorders; AKI, acute kidney injury; CKD, chronic
kidney disease; GFR, glomerular filtration rate; NKD, no known kidney disease;
SCr, serum creatinine.
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The answer to Question 1 requires ascertainment of an
index GFR/SCr as well during the prior 3 months. The index
GFR/SCr can be assigned as any of the GFR/SCr measures
during the interval of observation. The answer classifies
patients into three categories: NKD, AKD, and CKD.
Question 2 requires repeat ascertainment of kidney function
after the index measure. ‘‘No’’ indicates that the increase in
SCr or decrease in GFR after the index measure does not
Figure 6 |Chronic Kidney Disease Epidemiology Collaboration cohort changes in eGFR and final eGFR corresponding to KDIGO
definition and stages of AKI. Panels (a) and (b) show the final eGFR and the percent changes in eGFR, respectively, corresponding to the
KDIGO definition and stages of AKI. The horizontal line in panel a and b indicates the threshold value for AKD (o60ml/min per 1.73 m2 and
435% reduction in initial GFR, respectively). Points above the horizontal line indicate subjects who meet the SCr criteria for the definition of
AKI but do not meet eGFR criteria for the definition of AKD. AKD, acute kidney disorder/disease; AKI, acute kidney injury; eGFR, estimated
glomerular filtration rate; KDIGO, Kidney Disease: Improving Global Outcomes; SCr, serum creatinine. (Lesley Inker, personal
communication.)
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Figure 7 |GFR/SCr algorithm. See text for description. AKD, acute kidney disease/disorder; AKI, acute kidney injury; CKD, chronic kidney
disease; GFR, glomerular filtration rate; NKD, no known kidney disease; SCr, serum creatinine.
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meet AKI or AKD criteria; ‘‘Yes-D’’ indicates that increase in
SCr and decrease in GFR meets the AKD criteria but not AKI
criteria; and ‘‘Yes-I’’ indicates that increase in SCr meets AKI
criteria. Question 3 requires repeat ascertainment of GFR/
SCr 3 months after the index measure. ‘‘Yes’’ indicates GFR
460, indicating NKD. No indicates GFRo60, and based on
prior level of GFR, may indicate stable, new, or worse CKD.
Oliguria as a measure of kidney function
Although urine flow rate is a poor measure of kidney
function, oliguria generally reflects a decreased GFR. If GFR
is normal (approximately 125ml/min, corresponding to
approximately 107ml/kg/h for a 70-kg adult), then reduction
in urine volume to o0.5ml/kg/h would reflect reabsorption
of more than 99.5% of glomerular filtrate. Such profound
stimulation of tubular reabsorption usually accompanies
circulatory disturbances associated with decreased GFR.
Oliguria is unusual in the presence of a normal GFR and is
usually associated with the non–steady state of solute balance
and rising SCr sufficient to achieve the criteria for AKI. As a
corollary, if GFR and SCr are normal and stable over an
interval of 24 hours, it is generally not necessary to measure
urine flow rate in order to assess kidney function.
In principle, oliguria (as defined by the criteria for AKI)
can occur without a decrease in GFR. For example, low
intake of fluid and solute could lead to urine volume of less
than 0.5ml/kg/h for 6 hours or 0.3ml/kg/h for 24 hours. On
the other hand, severe GFR reduction in CKD usually does
not lead to oliguria until after the initiation of dialysis.
As described in Chapter 2.1, the thresholds for urine flow
for the definition of AKI have been derived empirically and
are less well substantiated than the thresholds for increase
in SCr. Urinary diagnostic indices, such as the urinary
concentrations of sodium and creatinine and the fractional
reabsorption of sodium and urea, remain helpful to
distinguish among causes of AKI, but are not used in the
definition (see Appendix D).
Kidney damage
Table 13 describes measures of kidney damage in AKD and
CKD. Kidney damage is most commonly ascertained by
urinary markers and imaging studies. Most markers and
abnormal images can indicate AKD or CKD, based on the
duration of abnormality. One notable exception is small
kidneys, either bilateral or unilateral, indicating CKD, which
are discussed separately below. Kidney damage is not a
criterion for AKI; however, it may be present. Renal tubular
epithelial cells and coarse granular casts, often pigmented and
described as ‘‘muddy brown’’, remain helpful in distinguish-
ing the cause of AKI, but are not part of the definition.
Small kidneys as a marker of kidney damage
Loss of renal cortex is considered a feature of CKD, and is
often sought as a specific diagnostic sign of CKD. Kidney size
is most often evaluated by ultrasound. In a study of 665
normal volunteers,69 median renal lengths were 11.2 cm on
the left side and 10.9 cm on the right side. Renal size
decreased with age, almost entirely because of parenchymal
reduction. The lowest 10th percentiles for length of the left
and right kidney were approximately 10.5 and 10.0 cm,
respectively, at age 30 years, and 9.5 and 9.0 cm, respectively,
at age 70 years.
Integrated approach to AKI, AKD, and CKD
Clinical evaluation is necessary for all patients with
alterations in kidney function or structure. The expectation
of the Work Group is that the diagnostic approach will
usually begin with assessment of GFR and SCr. However,
evaluation of kidney function and structure is not complete
unless markers of kidney damage—including urinalysis,
examination of the urinary sediment, and imaging studies—
have been performed. Table 14 shows a summary of the
diagnostic approach using measures for kidney function
and structure. Based on interpretation of each measure
separately, the clinical diagnosis indicated by an ‘‘X’’ can be
reached.
Table 13 |Markers of kidney damage in AKD and CKD
Markers AKD CKD
Pathology X X
Urinary markers
RBC/casts X X
WBC/casts X X
RTE/casts X X
Fine and coarse granular casts X X
Proteinuria X X
Blood markers (tubular syndromes) X X
Imaging
Large kidneys X X
Small kidneys — X
Size discrepancy — X
Hydronephrosis X X
Cysts X X
Stones X X
History of kidney transplantation — X
Kidney damage is not required for diagnosis of AKI. In the presence of AKI, findings
of kidney damage do not indicate a separate diagnosis of AKD.
AKD, acute kidney diseases and disorders; CKD, chronic kidney disease; RBC, red
blood cells; RTE, renal tubular epithelial cells; WBC, white blood cells.
Table 14 | Integrated approach to interpret measures of
kidney function and structure for diagnosis of AKI, AKD, and
CKD
Measures
Diagnosis GFR/SCr Oliguria Kidney damage Small kidneys
AKI X X
AKD X X
CKD X X X X
X indicates that the measures can contribute to the diagnosis indicated.
AKD, acute kidney diseases and disorders; AKI, acute kidney injury; CKD, chronic
kidney disease.
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